News Releases

August 10, 2023
Total Q2 revenue of $12.0 million and net income of $4.6 million Product sales and royalty revenue of $6.5 million up 175% from Q2 2022 and 22% from Q1 2023 $21.6 million of cash on hand Launched Betaine Anhydrous Management to hold conference call today at 4:30pm ET DEER PARK, Ill. , Aug.
May 11, 2023
Product sales and royalty revenue of $5.3 million up 144% from Q1 2022 and 52% from Q4 2022 Launched Betaine Anhydrous Management to hold conference call today at 4:30pm ET DEER PARK, Ill. , May 11, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an
March 16, 2023
Q4 2022 revenue of $8.5 million Q4 Product sales and royalty revenue up 220% from prior year and 9% from Q3 Q4 positive net income Management to hold conference call today at 4:30pm ET DEER PARK, Ill. , March 16, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq:
Displaying 1 - 10 of 11